{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/anticoagulation-oral/background-information/mode-of-action/","result":{"pageContext":{"chapter":{"id":"e9b14f86-2066-57e8-9b9f-65926e978b59","slug":"mode-of-action","fullItemName":"Mode of action","depth":2,"htmlHeader":"<!-- begin field a424deae-ba64-4143-b189-3b8d6f69e96b --><h2>How do anticoagulants work?</h2><!-- end field a424deae-ba64-4143-b189-3b8d6f69e96b -->","summary":"","htmlStringContent":"<!-- begin item f3b30078-c081-4cf7-b3de-0be08760b430 --><!-- begin field 002fae70-a2bf-421f-a556-a4ca3f9a0180 --><ul><li><strong>The main use of anticoagulants is to prevent thrombus formation or extension of an existing thrombus in the slower-moving venous side of the circulation,</strong> where the thrombus consists of a fibrin web enmeshed with platelets and red cells.<ul><li>Anticoagulants are of less use in preventing thrombus formation in arteries because in faster-flowing vessels, thrombi are composed mainly of platelets with little fibrin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>].</li></ul></li><li><strong>There are two main types of oral anticoagulants: </strong>vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs).<ul><li>Warfarin, the most commonly used VKA, is a coumarin derivative that acts by inhibiting vitamin K dependent clotting factors (II, VII, IX, X) in addition to the anticoagulant proteins C and S [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Micromedex, 2011</a>]. Warfarin has been used for decades as an anticoagulant. </li><li>DOACS (apixaban, dabigatran, edoxaban, and rivaroxaban) are anticoagulants with a novel mode of action [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>]:<ul><li>Apixaban, edoxaban, and rivaroxaban are direct and reversible inhibitors of factor Xa (inhibition of factor Xa prevents thrombin generation and thrombus development).</li><li>Dabigatran is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet aggregation.</li></ul></li></ul></li></ul><!-- end field 002fae70-a2bf-421f-a556-a4ca3f9a0180 --><!-- end item f3b30078-c081-4cf7-b3de-0be08760b430 -->","topic":{"id":"5e046307-14e1-50a6-9729-69af5ae00b78","topicId":"d64523b7-19f2-41a0-afd4-d1c0790cce30","topicName":"Anticoagulation - oral ","slug":"anticoagulation-oral","lastRevised":"January 2021","chapters":[{"id":"b5dcda3e-cc4c-56b5-9348-00f8e8eb8e32","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2424a367-7b32-59ea-8783-9d80a1a68c3c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"02a83663-a0e4-533a-a0a3-a6b15235867c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"31157a72-4e11-5ad4-8139-919ce4241f22","slug":"changes","fullItemName":"Changes"},{"id":"14f1139a-434d-530b-be52-9692e9271a76","slug":"update","fullItemName":"Update"}]},{"id":"67dfc47b-2285-596f-9f26-279a85f25dcc","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a4b943e8-803b-51b4-a154-3a58c4bbaf1a","slug":"goals","fullItemName":"Goals"},{"id":"1a8fff43-5d5a-5e06-803b-ea61542c56a4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a1c4ef1a-272a-56c2-bba9-b437e8b0e03d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"54bcfbdc-7506-5ca1-ae0c-e5ab55acb001","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2387aba8-f14a-5fc6-8335-485e08a6c959","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"dd9aca34-523a-570a-bb3f-422e7bf450a7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"772f3b00-3aa4-5b51-aad4-43ff44e987d3","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e9b14f86-2066-57e8-9b9f-65926e978b59","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"55f43edd-e0fd-5e66-a53b-36ef8f137cd3","slug":"licensed-indications","fullItemName":"Licensed indications"}]},{"id":"1432aebe-6008-53bc-915b-8f136a3cc1e6","fullItemName":"Management","slug":"management","subChapters":[{"id":"46bb380b-6d51-5ede-b5dc-78ec7987f404","slug":"apixaban","fullItemName":"Scenario: Apixaban"},{"id":"e4a2d921-e87f-5760-a17a-271fefa9d1c4","slug":"dabigatran","fullItemName":"Scenario: Dabigatran"},{"id":"e0aace92-5b9a-53c2-af09-6318f0911654","slug":"edoxaban","fullItemName":"Scenario: Edoxaban"},{"id":"015cbcc5-4efe-568f-9643-d7a22d37b286","slug":"rivaroxaban","fullItemName":"Scenario: Rivaroxaban"},{"id":"693e35a4-4b44-514c-847c-855a53793f98","slug":"warfarin","fullItemName":"Scenario: Warfarin"}]},{"id":"3d346e04-bfd5-53aa-9cbe-bee5c6a912bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"76dbe1dd-0d3b-50e8-9472-5af55550c77a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5f762de3-78b6-55d7-b9bb-cc3f1cb77bea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c725a38-4d35-5fbd-bd5d-b48afc70e783","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2b9eb7d5-9bc8-5af8-b91f-75e9b1480d83","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"33630559-9216-56bf-9890-6bbe997245bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51bd3b51-3e20-5f51-a925-74b2c904fd53","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"54dbb8de-8bee-5c53-b63b-9645b55e6b5d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"772f3b00-3aa4-5b51-aad4-43ff44e987d3","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}